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Abstract 
 
Background: To investigate the effect of Eurycoma longifolia Jack root extract on serum lipids in rats. Methods: 
Twenty-six mature male albino Wistar rats were used in this study. A group of 18 rats were fed a high fat and high 
cholesterol diet for 4 weeks, after which their lipid profile was compared to the control group, who were kept on a 
normal diet. The rats were then further divided into three groups, the Cf group that continued to feed on a high fat and 
cholesterol diet only, and group A and group B who continued on a high fat diet with the addition of 5 mg/kg and 10 
mg/kg of Eurycoma longifolia Jack root extract respectively for 4 weeks. After the 4 week period, the rat’s lipid profiles 
were analysed again. Results: Group A and B showed significant total cholesterol reduction when compared to the Cf 
group, 140 ± 7.23, 139.63 ± 7.95, 192.14 ± 8.96 mg/dL respectively (p < 0.001). The total cholesterol/HDL ratio in 
group A was 5 however there was a sharp increase in group B to a high-risk level of 9.2 indicating a significant drop in 
HDL levels. The LDL level increased significantly in both group A and B compared to the Cf group. Conclusions: 
Eurycoma longifolia Jack root extract is effective in lowering total cholesterol, however the dose needs to be adjusted to 
prevent an excessive decrease in HDL levels.  
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Introduction 
 
Over the past three decades there has been an increasing 
trend to use natural products rather than conventional 
treatments as remedies for many diseases.1 A study 
conducted in the USA showed that a high percentage of 
well-educated people prefer to use alternative medicines.2 
 
A very common tropical herbal plant in Southeast Asian 
countries is Eurycoma longifolia Jack (E.L), which is 
also known as Tongkat Ali. This tree is found in the 
forests of Burma, China, Thailand, Malaysia, Sumatra, 
Borneo, and the Philippines.3 The plant’s roots, stems, 
and bark are used as folk medicines for the treatment of 
many conditions including fevers, sexual dysfunction, 
dysentery, and fatigue. Traditionally the water decoction 
of E. longifolia root is consumed orally and research has 
shown a wide range of biological activities including 
antimalarial, cytotoxic, antiulcer, and antipyretic properties. 
These properties may be attributed to the various 
quassinoids, squalene derivatives, biphenylneolignans, 
tirucallane-type triterpenes, canthine-6-one, and l~-
carboline alkaloids found in the plant. However, the 
main use of this plant is as a sexual enhancer with 
studies proving that it can raise the serum testosterone 
levels leading to improved strength and power during 
sexual activities and an increase in male virility.9 
 
Recent studies have also shown that the E.L root has 
antibacterial and antifungal properties against human 
pathogenic bacteria and fungi.10,11 Additionally, antioxidant 
and anti-inflammatory properties were also detected in 
the root extract.12 
 
Lipids serve several important physiologic functions 
within the human body, such as stabilising the cell 
membrane and facilitating membrane transport. They 
are also important for the biosynthesis of hormones and 
the production of bile acids for the absorption of fat in 
mammals. Lipids are insoluble in water and must be 
packaged into lipoproteins to circulate within the plasma. 
The core of the lipoprotein, containing cholesterol ester 
and triglycerides (TG), is nonpolar and hydrophobic, 
and the outer layer of the lipoprotein particle (containing 
free cholesterol, phospholipid, and specific apolipoproteins) 
is polarised, permitting the lipoprotein particles to be 
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transported in the circulation. Each lipoprotein class 
(chylomicrons, very low density lipoprotein (VLDL), 
Intermediate density lipoprotein (IDL), low density 
lipoprotein (LDL), and high density lipoprotein (HDL) 
varies in size, density, and lipid composition within the 
core of the particle.13 
 
LDL particles carry the majority of the cholesterol in the 
blood, supplying cholesterol to the cells. LDL receptors 
in peripheral cells or the liver bind with LDLs and clear 
it from the blood and the peripheral cells utilise LDL 
cholesterol. LDL is an atherogenic lipoprotein particle, 
and it is established that higher levels of LDLs are 
associated with increased cardiovascular disease risk.14 
 
HDL particles are synthesised and catabolised in the 
liver and intestines. Nascent HDL obtains free cholesterol 
from peripheral tissues. It is well established that 
increased HDL levels are associated with a decreased 
risk of coronary heart disease, whereas reduced HDL 
levels increase risk. The cardioprotective role of HDLs 
is to facilitate the transfer of cholesterol from atherogenic 
lipoproteins and peripheral tissues to the liver.15 
 
Hyperlipidaemia involves abnormally elevated levels of 
any or all lipids and lipoproteins in the blood.16 Lipid and 
lipoprotein abnormalities are common in the general 
population and are regarded as a modifiable risk factor 
for cardiovascular disease due to their influence on 
atherosclerosis.17 
 
Previous studies addressed the effect of testosterone 
supplementation on the serum lipid levels of men and 
found that the administration of testosterone improved 
lipid metabolism by decreasing total cholesterol and 
low-density lipoprotein cholesterol.18,19 Researchers 
have also found that testosterone administration slows 
the process of atherosclerosis and leads to attenuation of 
fatty streaks.20 
 
Because the consumption of Eurycoma longifolia Jack 
root leads to a rise in serum testosterone levels, we 
hypothesised that the root extract would indirectly lead 
to a decrease in serum lipid levels. 
 
Methods 
 
The water soluble, freeze-dried extract was purchased 
from the Ljack Sdn Bhd Company in Malaysia; the 
product was supported by a certificate indicating it was 
pure and of a high concentration. 
 
Twenty six mature male albino Wistar rats were used in 
this study. The sample size was calculated according to 
the resource equation method.21 They were housed in 
standard cages and fed on standard pellets for 7 days 
before commencing the experiment. Serum cholesterol, 
HDL, LDL, and testosterone were analysed using 
commercial kits manufactured by Abnova, with kit 
numbers KA0829, KA1671, and KA0309 respectively. 
They were purchased from Axon scientific Sdn Bhd 
Malaysia. 
 
Eight rats were randomly chosen to represent the control 
group C; they did not receive any dietary changes or 
E.L root extract throughout the experiment. At the start 
of the experiment fasting serum cholesterol, LDLs, and 
HDLs were recorded for the control group. The rest of 
the 18 rats were maintained exclusively on a high fat 
and high cholesterol diet for 4 weeks. At the end of this 
period we analysed the fasting cholesterol, HDLs, and 
LDLs for the high fat fed rats. 
 
The 18 high fat fed rats were randomly split into three 
groups; the control group that continued to feed on a 
high fat diet only (Cf), and group A and B both of which 
continued to be fed on a high fat diet with the addition 
of E.L root extract. Group A received 5 mg/kg, and 
group B received 10 mg/kg of E.L extract twice daily that 
was dissolved in 10 mL of distilled water and manually 
fed to the rats using a mouth gavage. The treatment 
continued for 4 weeks at the end of which, the fasting 
serum lipid and testosterone analysis were repeated. 
 
Statistical analysis. Statistical analysis of the data was 
carried out using Statistical Package for Social Sciences 
(SPSS) version 20.0. One-way analysis of variance and 
the Tukey post hoc test for average comparison were 
completed. Mean values ± standard deviation were 
calculated. Values of p < 0.05 were considered statiscally 
significant. 
 
Ethical approval. This research was approved by the 
Kulliyyah of Dentistry Research Committee and the 
Research Management Centre, of the International Islamic 
University of Malaysia, Kuantan Campus, 2100 Kuantan, 
Pahang, Malaysia. 
 
Results 
 
The results of this study showed that there was a 
statistically significant increase in fasting levels of 
Cholesterol, HDLs, and LDLs in the rats fed on high 
cholesterol diets when compared to the control group (p 
< 0.001). This implies that the high cholesterol diet caused 
an elevation of blood lipids. The cholesterol/HDL ratio 
was maintained at the same level (Table1).  
 
After administration of the E.L extract the level of blood 
lipids found in group A showed a statistically significant 
reduction in total cholesterol levels when compared to the 
Cf group, 140 ± 7.23, 192.14 ± 8.96 mg/dL respectively. 
The total cholesterol of group A dropped down to nearly 
the same level as the control group, 136.6 ± 3.77 mg/dL. 
The levels of LDLs significantly increased to 74.81 ± 
2.21 mg/dL (p < 0.001). However, the HDL levels dropped 
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insignificantly to 27.66 ± 1.93 mg/dL (p = 0.209). The 
total cholesterol/HDL ratio of group A was equal to 5 
(Table 2).  
 
The total cholesterol levels were significantly reduced 
in group B when compared with the Cf group, with their 
levels being 139.63 ± 7.95 and 192.14 ± 7.76 mg/dL, 
respectively (p < 0.001). However, the reduction of total 
cholesterol in group B was not statistically significant 
from group A (p = 0.729) (Table 3 and Table 4).  
 
The changes to HDLs and LDLs in group B are more 
pronounced as both the decrease in HDLs and the 
increase in LDLs are statistically significant when 
compared with the Cf group (p < 0.001). Due to the 
significant decrease in HDLs, the total cholesterol/HDL 
ratio increased greatly to 9.2 in group B (Table 3). 
 
When comparing the results of group A and B, we can 
see that the decrease in cholesterol seen in group B is 
not significant when compared to group A (p = 0.729). 
However, the decrease in HDLs and the increase in 
LDLs in group B are statistically different than group A 
(p < 0.001) (Table 4). 
 
Testosterone levels were slightly increased in group A 
when compared to the Cf group, however the increase 
was not significant. In group B, there was a sharp rise in 
testosterone levels to 1.75 ± 0.10, which was significantly 
higher than the Cf group (p < 0.001). In comparing the 
testosterone levels between group A and B, there was a 
statistically significant increase in testosterone in group 
B (p < 0.001) (Table 2, 3, and 4). 
 
Table 1.  Shows the Values of Serum Lipids in the Control 
Group before and after a High Cholesterol Diet 
 
   Control (C)  After high fat diet 
  Mean mg/dL ± SD Mean mg/dL ± SD 
Cholesterol 136.60 ± 3.77 192.14 ± 5.79* 
HDL 22.45 ± 1.13 29.24 ± 1.11* 
LDL 33.36 ± 1.26 48.86 ± 1.34* 
Cholesterol/HDL 6.08 6.57  
*statistically significant p < 0.001  
 
 
Table 2.  Shows the Mean Fasting Serum Lipid Levels in 
the Control Group on a High Fat Diet (Cf ) and 
Group A 
 
  Cf Group A 
  Mean ± SD Mean ± SD 
Cholesterol mg/dL 192.14 ± 8.96 140 ± 7.23* 
HDL mg/dL 29.24 ± 1.22 27.66 ± 1.93  
LDL mg/dL 48.86 ± 1.79 74.81 ± 2.21* 
Testosterone (ng/mL) 0.79 ± 0.07  0.89 ± 0.16   
Chol/HDL 6.50 5.00 
*statistically significant p < 0.001 
Table 3.  Shows the mean Fasting Serum Lipid Levels in 
the Control Group on a Fat Diet (Cf) and Group B 
 
  Cf Group B 
  Mean ± SD   Mean ± SD 
Cholesterol 192.14 ± 7.76 139.63 ± 7.95* 
HDL 29.24 ± 1.88 15.02 ± 0.83* 
LDL 48.86 ± 2.06 104.89 ± 2.55* 
Testosterone (ng/mL) 0.79 ± 0.07 1.75 ± 0.10* 
Chol/HDL 6.50 9.20 
*statistically significant p < 0.001 
 
 
Table 4. Comparison between Group A and B 
 
  A B 
  Mean ± SD     Mean ± SD 
Cholesterol 140 ± 7.23 139.63 ± 7.95  
HDL 27.66 ± 1.93 15.03 ± 0.83* 
LDL 74.81 ± 2.21 104.89 ± 2.55* 
Testosterone (ng/mL) 0.89 ± 0.16  1.75 ± 0.10* 
Cholesterol/HDL 5.00 9.20 
*statistically significant p < 0.001 
 
Discussion 
 
Modern lifestyle and the increased consumption of a 
high fat diet and processed foods has led to an increase 
in the serum lipids across different age groups in the 
population. This has increased the need for medical 
intervention using drugs or invasive techniques to 
prevent or treat coronary heart disease, a common 
consequence of high blood lipids.22 
 
Raised total cholesterol is a significant risk factor for 
coronary heart disease, and the risk is significantly higher 
in men than women.23 The currently available lipid 
lowering agents are not free from side effects, some of 
which are quite serious.24 
 
The current trend in research is to look for natural 
resources with medical applications that are safe for 
human use as well as being environmentally friendly. 
 
Many recent studies have documented the inverse 
relationship between testosterone and cardiovascular 
related mortality, stating that low serum testosterone is 
associated with increased risk of cardiovascular disease 
and mortality, and that increasing endogenous testosterone 
can lead to higher survival rates.25-28 
 
Eurycoma longifolia Jack root extract is a well-known 
natural product that has been documented as safe for 
human use and can be used to increase testosterone 
levels in males.29 
 
In this study, we fed sample rats a high cholesterol diet, 
which lead to an actual rise in cholesterol levels when 
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compared to the rats fed a normal level. We then used two 
different concentrations of E.L root extract administered 
twice daily.  
 
In a previously conducted study using the same doses of 
E.L root extract, the 10 mg/kg dose resulted in very 
sharp rise in testosterone levels when compared to the 5 
mg/kg dose.29 
 
In both treatment groups there was a significant lowering 
of cholesterol levels in comparison with the Cf group. 
However, when comparing the cholesterol levels of group 
A and group B, there was no statistically significant 
difference (p = 0.729), indicating that an increased E.L 
dose does not improve lipid lowering effects (Table 4). 
 
The effect of E.L extract on HDLs and LDLs appears to 
be reciprocal as E.L caused a decrease in HDLs and an 
increase in LDLs, an effect that is considered unfavourable. 
However, studies have shown that the most important 
predictor of cardiovascular risk is the total cholesterol/HDL 
ratio and not high levels of LDLs alone. It has been 
reported that subjects with low LDL cholesterol levels 
and high total cholesterol/HDL ratios (>5) had a 2.5 
times higher incidence of CHD than those with similar 
LDL cholesterol levels and low total cholesterol/HDL 
cholesterol ratios.30 
 
Looking at the effect of E.L extract on the cholesterol/ 
HDL ratio, we found that in group A the ratio was equal 
to 5, which means that it is still within the safe range, 
however for group B the ratio had increased well beyond 
safe levels. The rise in the ratio and the consequent sharp 
drop in HDL levels seen in group B can be explained by 
the effect of sharply increasing testosterone levels in 
this group. Previous studies have shown the effect of 
testosterone on lowering HDL cholesterol, a phenomenon 
observed in athletes using androgenic-anabolic steroids.31 
This effect has also been achieved consistently with the 
administration of supraphysiologic doses of oral androgens 
in young men, however it is far less consistent when 
testosterone therapy is used at physiologic doses to 
restore eugonadal serum levels, particularly in older 
men. 32,33 
 
As such, we can expect that treatment with 5 mg/kg of 
E.L extract should maintain testosterone levels close to 
the normal physiological range to help reduce total 
cholesterol levels, whilst also maintaining a safe 
cholesterol/HDL ratio. While the higher dose of 10 
mg/kg led to a significantly higher level of testosterone 
leading to a sharp rise in the cholesterol/HDL ratio and 
no increased benefit of cholesterol lowering ability. 
 
Conclusions 
 
E.L root extract is beneficial in lowering total cholesterol 
level, however the dose should be regulated to prevent 
unnecessary lowering of HDL levels. This extract may 
be useful to lower total cholesterol as well as helping to 
return testosterone to normal physiological levels in 
elderly males with hypercholesterolaemia. 
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